宝丽亚说明书
AZ AQUATAR家族产品系列介绍说明书
9F3C
1F3C
PFOS
CF2 CF2 CF2 SO3OH
CF2 CF2 CF2
PFOA
CF2 F3C
CF2 CF2 CF2
C8 Telomer
CF2 CF2 CF2 CH2CH2OH CF2 CF2 CF2 CF2
CF2
CF2
CF2
COOH
AZ Electronic Materials Confidential
(1.44/1.48/1.56)
(1.40/1.43/1.45)
AQUATAR-3S (1.42/1.44/1.49)
PFOS
AQUATAR-6 (1.40/1.43/1.45)
Fluoro Polymer
AQUATAR-8A (1.41/1.45/1.52)
AQUATAR-8B
for KrF “N” resist
4
AZ, the AZ logo, BARLi, Aquatar, nLOF, Kwik Strip, Klebosol, and S5pinfil are
registered trademarks and AX, DX, HERB, HiR, MiR, NCD, PLP, Signiflow,
SWG, and TARP are trademarks of AZ Electronic Materials.
SWG, and TARP are trademarks of AZ Electronic Materials.
2.4 Resist swing reduction effect in 365nm application
Substrate TARC Develop
: Silicon with HMDS(90C/60s) : 64nm FT, NO PAB : AZ 300MIF(2.38%) , puddle 60s
ColiComplete 产品说明书
Page 1 of 2 ColiComplete ®AOAC Official Method 992.30General DescriptionColiComplete ® contains 5-bromo-4-chloro-3-indolyl-ß-Dgalactopyranoside (X-Gal) and 4-methyl umbelliferyl-ß-D-glucuronide (MUG). Discs are added to LST inoculated with selected dilutions of samples. Samples are incubated at 35–37 °C and examined after 24 and 48 ±2 h for confirmed total coliforms and after 30 ±2 h for confirmed E. coli results. ß-Galactosidase, from coliforms present in samples, cleaves X-Gal into 5-bromo-4-chloro-indoxyl intermediate which undergoes oxidation to yield water-insoluble blue dimer, visually detectable on disc or in surrounding medium as confirmed positive result for total coliform activity. ß-Glucuronidase, from E. coli present in samples, cleaves MUG into glucuronide and methyl umbelliferone which fluoresces under long wave UV light (366 nm) as confirmed positive result for E. coli presence.NOTE : As E. coli O157:H7 does not produce ß-glucuronidase, ColiComplete ® is not suitable for the detection of E. coli O157:H7.A. Sample PreparationPrepare appropriate serial dilutions as indicated in FDA Bacteriological Analytical Manual (BAM), or AOAC Official Methods of Analysis according to sample type.B. InoculationInoculate LST tubes with appropriate sample dilution series selected to determine MPN levels or presence/absence of total coliforms and E. coli in sample. Aseptically add a single ColiComplete ® disc to each tube. Incubate at 35–37 °C.C. Reading ColiComplete ®a. For total coliforms — After at least 24 h incubation, examine each tube for visually detectable blue color on disc or in surrounding medium. Presence of blue color indicates confirmed positive result for total coliforms.NOTE: A wide range of blue color intensity may be expected, depending on sample composition and microflora. All blue reactions are positive regardless of intensity of color.Reincubate at 35–37 °C. After additional 24 ±2 h re-examine. Continued absence of blue indicates negative result; presence of blue indicates confirmed positive result for total coliforms. Read and record the MPN code or presence/absence of total coliforms in the sample.b. For E.coli — After 30 ±2 h from start of initial incubation, examine tubes under long-wave UV light (366 nm). Fluorescent tubes indicate confirmed positive result for E. coli. Read and record the MPN code or presence/absence of E. coli in the sample.D. CONTROLSPositive and negative controls should be used to facilitate interpretation of MUG fluorescent reaction. Use one known positive E. coli tube and two negative controls - one non -E. coli /coliform tube (e.g., Klebsiella spp.) and one uninoculated media tube.NOTE: Use borosilicate glass tubes, flint glass gives fluorescence that may be misinterpreted for a positive result.Lit. No. MK_UG4655EN Merck KGaAFrankfurter Strasse 25064293 DarmstadtGermanyPage 2 of 2 E. Method Modification for Certain JuicesApplicable to juice products/processors which rely on treatments that do not come into direct contact with all parts of the juice, as contained in 21 CFR Part 120: Rules and Regulations. Hazard Analysis and Critical Control Point (HAACP); Procedures for the Safe and Sanitary Processing and Importing of Juice; Final Rule. Vol 66 No. 13. 6137-6202. Use the modified method “Analysis for Escherichia coli in Citrus Juices - Modifi cation of AOAC Official Method 992.30” as stated in Section 120.25 (a).F. StorageStore unused discs at 2–8 °C (36–46 °F) in a sealed container, with desiccant.G. DisposalAfter use, all tubes must be steam-sterilized at 121 °C for at least 30 min before discarding. For in-vitro diagnostic use only.Manufacturing EntityBioControl Systems, Inc, 12822 SE 32nd St, Bellevue, WA 98005, USA.BioControl Systems, Inc is an affiliate of Merck KGaA, Darmstadt, Germany.。
奥利ン普亚瓷砖产品说明书：拉里克系列
LARIX Series PORCELAIN15 x 75 cm (6 x 30) RF.LX.FRS.063015 x 75 cm (6 x 30)RF.LX.NAT.063015 x 75 cm (6 x 30)RF.LX.SUN.063015 x 75 cm (6 x 30)RF.LX.SHA.0630FRESH (Light Gold)NATURAL(Beige)SUN(Dark Beige)SHADE(Grey)All items shown in this document are part of Olympia’s stocking program. For special orders, please contact your Olympia Tile Sales Representative.15 x 75 cm (6 x 30) RF.LX.NAT.0630.DECO 15 x 75 cm (6 x 30)RF.LX.SUN.0630.DECO15 x 75 cm (6 x 30)RF.LX.SHA.0630.DECONATURAL (Beige)SUN(Dark Beige)SHADE(Grey)All items shown in this document are part of Olympia’s stocking program. For special orders, please contact your Olympia Tile Sales Representative.25 x 75 cm (10 x 30)Linear Muretto ListelloRF.LX.FRS.1030.MLS25 x 75 cm (10 x 30)Linear Muretto ListelloRF.LX.SUN.1030.MLS25 x 75 cm (10 x 30)Linear Muretto ListelloRF.LX.NAT.1030.MLS25 x 75 cm (10 x 30)Linear Muretto ListelloRF.LX.SHA.1030.MLSFRESH (Light Gold)SUN (Dark Beige)NATURAL (Beige)SHADE (Grey)All items shown in this document are part of Olympia’s stocking program. For special orders, please contact your Olympia Tile Sales Representative.Technical data is supplied by the manufacturer and is subject to change at any time. Olympia does not provide warranties as to thespecifications of any product.Water Absorption ISO 10545-3< 0.5%ConformsLARIX SERIESTests Performed -- Results ConformColour VariationMemberMember of Canada Green BuildingCouncilMember of U.S. Green BuildingCouncilFor information concerning LEED, please contact our Sales Representative6” x 30” Tile and Decor 78.5038.504810” x 30” Muretto Listello48.1035.2020Packing DetailsExamples of Recommended ApplicationsResidentialLight Commercial Medium Commercial Heavy CommercialIndoorOutdoorWallFloorCeramic Tile Distributors ofAmerica (CTDA)The Terrazzo, Tile, and Marble Association ofCanadaMarble Instituteof AmericaTaskGrout Sealing MORE™ Grout, Ceramic &Porcelain Sealer Ready to use Commercial: 1-3 Years Residential: 5-8 YearsDaily Maintenance MORE™ Stone and TileCleaner 1 : 128 Ratio Daily Deep Cleaning MORE™ Alkaline Cleaner 1 : 4 Ratio As Needed Grout Haze- CementitiousMORE™ Acidic Cleaner 1 : 4 Ratio As Needed Grout Haze - Epoxy / UrethaneMORE™ Coating Stripper*Ready to useAs Needed* Always test in an inconspicuous area to make sure the product is achieving the desired results and is not damaging the finish of the surface.SURFACE PREPARATION (If Required)• Floor levelling: 59 Flex Flo / 5900 Flex Flo Plus Self Levelling Underlayment • Waterproofing: WP900 Waterproof Membrane• Crack Isolation/Uncoupling: Flexilastic 1000 Crack Isolation Membrane / FlexMat Uncoupling Membrane* For a complete listing of FLEXTILE products and accessories including Sound Control, In‐Floor Heating, and further setting options, please visit SHADE (Grey)FRESH (Light Gold)It is Olympia Tile’s policy to stock all items for sale. Should you require additional sizes, finishes or colours, Olympia has a Special Order Department to help find exactly what you are looking for. Please contact your Olympia Tile Sales Representative for more details. Note that minimum order quantities and longer lead times apply to all special order items.Colour may vary slightly from images shown. It is highly recommended to view physical samples of tile prior to purchase. Note that shade variations between tiles is characteristic and adds to the inherent beauty of the product. Please visit a showroom near you or request a sample from your Olympia Tile Sales Representative.LARIX SERIES: Board MEF-183 / Folder FL-774CORPORATE OFFICE 701 Berkshire Lane North Minneapolis (Plymouth) Minnesota 55441 T: 763 545 5455 F: 763 542 9830 FLORIDAALPHA TILE & STONE 2443 East Meadow Blvd.Tampa , Florida 33619T: 813 620 9000TollFree:180****9000F: 813 621 0606 10898-A Metro Parkway Fort Myers , Florida 33966T: 239 275 8288TollFree:180****8288F: 239 275 01162603 Ace RoadOrlando , Florida 32804T: 407 293 3993TollFree:180****3993F: 407 293 17791808 Whitfield Ave.Sarasota , Florida 34243T: 941 727 7433TollFree:180****3484F: 941 727 7381IOWAKATE-LO TILE & STONE 4251 N.W. Urbandale Dr. Des Moines (Urbandale)Iowa 50322T: 515 270 4920TollFree:180****1387F: 515 270 7035NORTH DAKOTAKATE-LO TILE & STONE Resource Centre300 Northern Pacific Ave.Suite 106Fargo , North Dakota 58102T: 701 478 8087F: 701 478 8084MICHIGANBEAVER TILE & STONE 24700 Drake Rd.Detroit West(Farmington Hills)Michigan 48335T: 248 476 2333TollFree:180****0551F: 248 476 46361700 Stutz Dr., Suite 101Detroit North (Troy)Michigan 48084T: 248 649 5552F: 248 649 07412780 Enterprise Ct.Saginaw , Michigan 48603T: 989 790 5851TollFree:180****0897F: 989 790 031113085 23 Mile Rd.Detroit East(Shelby Township)Michigan 48315T: 586 991 0780TollFree:180****5395F: 586 991 07841694 Gezon ParkwayGrand Rapids, (Wyoming)Michigan 49509T: 616 534 2883TollFree:180****0727F: 616 534 4784MINNESOTAKATE-LO TILE & STONE 701 Berkshire Lane North Minneapolis (Plymouth)Minnesota 55441T: 763 545 5455TollFree:180****3026F: 763 542 9830NEBRASKAKATE-LO TILE & STONE 13211 Chandler Road Suite 400Omaha (La Vista)Nebraska 68138-3703T: 402 614 9010TollFree:187****6636F: 402 614 0989NEW JERSEYNEW JERSEY TILE & STONE70 Newfield Avenue Raritan Center, EdisonNew Jersey 08837T: 732 512 1818TollFree:180****8453F: 732 512 1881NEW YORKDOBKIN TILE & STONE 51 Benbro DriveBuffalo (Cheektowaga)New York 14225T: 716 684 1200TollFree:180****1414F: 716 684 129448 Railroad Avenue Albany (Colonie)New York 12205T: 518 489 6803TollFree:180****5769F: 518 489 6806OREGONTHOMPSON TILE & STONE 4472 NW Yeon Avenue PortlandOregon 97210T: 503 225 1273TollFree:180****4092F: 503 222 0731WISCONSINLEXCO TILE & STONE 1616 S. 108th Street MilwaukeeWisconsin 53214T: 414 771 2900Toll Free: 1 800-242-2249F: 414 771 9153WASHINGTONTHOMPSON TILE & STONE 3900 East Alki SpokaneWashington 99208T: 509 535 2925TollFree:180****2555F: 509 534 5218711 S. Fidalgo Street SeattleWashington 98108T: 206 900 7331TollFree:180****4093F: 206 294 5933575 Strander Blvd.TukwilaWashington 98188T: 206 575 7976F: 206 575 7484OL YMPIA TILE + STONE INTERNATIONAL INC.OL YMPIA TILE (USA), INC.TORONTO121 30th Street l Toronto l Ontario l M8W 3C1T: 416 255-1111 l Toll Free: 1 800 699 3623 l F: 416 255-1729VANCOUVER2969 Lake City Way l Burnaby l British Columbia l V5A 2Z6 T: 604 420-4914 l Toll Free: 1 888 236 4486 l F: 604 420-0936FLEXTILE LTD.MANUFACTURING PLANTS CORPORATE OFFICE AND SHOWROOM TORONTO1000 Lawrence Ave. West Ontario M6A 1C6T: 416 785 6666TollFree:180****1613F: 416 785 9682VAUGHAN100A Royal Group CrescentOntario L4H 1X9T: 905 266 0420F: 905 266 0423VANCOUVER2350 Willingdon Ave.BurnabyBritish Columbia V5C 5J6T: 604 294 2244TollFree:180****9441F: 604 294 0528CALGARY3308 - 11th Street S.E.Alberta T2G 3G8T: 403 287 1070TollFree:180****8182F: 403 243 1888EDMONTON11540 - 163rd Street Alberta T5M 3T3T: 780 452 5050TollFree:180****4438F: 780 451 4391WINNIPEG560 Sheppard Street Manitoba R2X 2P8T: 204 633 5736TollFree:180****8017F: 204 632 4644WINDSOR4145 7th Concession Rd Ontario N9A 6J3T: 519 966 2500TollFree:187****5953F: 519 969 2407LONDON234 Exeter Road Ontario N6L 1A3T: 519 652 5011TollFree:180****4690F: 519 652 5021HAMILTON 75 Milburn Road Ontario L8E 3A3T: 905 560 5520TollFree:180****1370F: 905 578 3593OTTAWA2480 Don Reid Drive Ontario K1H 1E1T: 613 736 9570TollFree:180****1864F: 613 736 9563MONTREAL 555 rue Locke Ville St-Laurent, Quebec H4T 1X7T: 514 345 8666TollFree:180****1954F: 514 345 8825QUEBEC2405 rue Watt Quebec G1P 3X2T: 418 657 5557TollFree:180****5516F: 418 657 6708HALIFAX55 Akerley Boulevard Dartmouth, Nova Scotia B3B 1M3T: 902 468 9260TollFree:180****7790F: 902 468 0011TORONTO 22 Dufflaw RoadToronto, Ontario M6A 2W1 T: 416 785 9555 ext 320F: 416 781 4521VAUGHAN100A Royal Group Crescent Vaughan, Ontario L4H 1X9 T: 905 266 0420F: 905 266 0423SLAB DIVISION。
Infinity Alpha Center Bois Cl Codic系列产品使用说明说明书
MARQUE: INFINITY REFERENCE: ALPHA CENTER BOIS CL CODIC: 0323098INSTRUCTION MANUALBEDIENUNGSANLEITUNGMODE D’EMPLOI MANUAL DE INSTRUCCIONES GEBRUIKSAANWIJZINGMANUALE D’ISTRUZIONIBRUGSVEJLEDNING MALLISTON KÄYTTÖOHJE MANUAL DE INSTRUÇÕESMode d’emploi des enceintes Série ALPHA InfinityNous vous félicitons pour votre choix des enceintes Série ALPHA Infinity. Les instructions contenues dans ce manuel vous aideront à tirer le meilleur parti de ces enceintes.EMBALLAGELe conditionnement de vos enceintes Série ALPHA a été réalisé pour les protéger de tout dommage qui pourrait résulter d’une manutention peu délicate ou du transport. Nous vous conseillons vivement de les conserver pour les déménagements ultérieurs ou pour d’éventuelles opérations de maintenance.POSITIONNEMENTUn positionnement correct des enceintes au sein de la pièce est de première importance pour obtenir le meilleur son possible. Les réflexions sur des murs réverbérants, l’emplacement du mobilier, l’existence de tentures ou rideaux épais, la présence de baies vitrées etc. peuvent influencer notablement la qualité du son, ou l’équilibre et la bonne restitution de l’image stéréo. Il est essentiel d’essayer plusieurs solutions pour déterminer quel positionnement donne la meilleure balance générale et la meilleure image sonore. Pour un effet stéréo optimum les enceintes devraient êtres distantes d’au moins 2 à 3 mètres. Parfois, le fait de les tourner légèrement àl’intérieur, vers l’auditeur, augmente la spatialisation et donne une représentation sonore plus exacte. Évitez, autant que possible, de placer ces enceintes contre les murs ou dans les angles, qui engendrent une image stéréo médiocre et un excès de graves. Si vous devez, pour des raisons techniques, placer les haut-parleurs au dessus du niveau des oreilles, inclinez-les vers le bas pour diriger les tweeters dans l’axe d’écoute de l’auditeur.INSTALLATION DES POINTES DE DECOUPLAGETous les modèles posés au sol sont équipés de pointes de découplage destinées àisoler l’enceinte des vibrations retransmises par le sol.Pour les installer, suivez les instructions1.R etournez l’enceinte à l’envers,reposée là sur sa partie supérieure.2.Enfilez un écrou au bout de chaquepointes de découplage, jusqu’à cequ’il atteigne la partie non filletée.3.Vissez les pointes de découplagedans les emplacements prévus sur labase de l’enceinte.4.Réglez-les pour qu’elles aient la mêmehauteur, puis dévissez le contre-écrou pour les bloquer et garder ceréglage.7CONNEXIONSVérifiez bien que tous les appareils soient éteints avant d’effectuer les branchements.Pour brancher les enceintes au récepteur ou à l’amplificateur, utilisez un câble isolé, àdeux conducteurs. Votre revendeur Infinity pourra vous conseiller sur les modèles adaptés, mais nous recommandons de toutes façons un diamètre supérieur à 1,3 mm (16 AWG), et même nettement plus si vos enceintes sont distantes de plus de 10 m de leur ampli ou récepteur. Le câblage est une partie importante des systèmes audio.Vous pouvez même légitimement souhaiter faire des essais comparatifs chez votre revendeur de différents ensembles ou types de câbles qu’il propose. Pour chaque voie, la borne rouge de l’enceinte doit être reliée à la borne repérée rouge ou (+) de l’ampli (ou récepteur), et la noire à sa correspondante noire ou (-). De cette manière,les enceintes seront «en phase » et non en opposition. Le fait de brancher les enceintes hors-phase ne les endommagera pas, mais réduira à la fois la séparation stéréo et la qualité des basses. La plupart des conducteurs pour haut-parleurs sont repérés soit par leur couleur, soit par la présence d’une gouttière ou d’une rainure sur le gainage d’un des deux fils. Cela permet d’identifier facilement le fil à connecter àchaque terminal. Si vous voulez branchez plus d’une paire d’enceintes sur un ampli ou un récepteur, vérifiez bien auprès de votre revendeur ou du constructeur de l’ampli qu’il puisse en supporter la charge en toute sécurité.clippent » et génèrent une distorsion qui des conditions limites et dangereuses pour les éléments les plus faibles du système.Plus l’ampli que vous utilisez est petit, et plus grand est le risque d’écréter, et donc de mettre en danger les tweeters. Les réglages graves/aigus de l’ampli ou du récepteur peuvent aussi exagérer ou renforcer ce phénomène. Nous vous conseillons donc de 8toujours utiliser un ampli ou un récepteur susceptible de faire fonctionner vos enceintes ALPHA raisonnablement fort tout en gardant un son clair et non distordu. ENCEINTE CENTRALE ALPHALa série ALPHA d’INFINITY dispose enceinte centrale dédiée. L’ALPHA Center est amagnétique ce qui vous permet de la positionner directement et en toute sécuritésur, ou sous votre téléviseur. La face avant de l'ALPHA Center est conçue pour s’aligner le mieux possible à la forme du téléviseur. L’ALPHA Center se branche sur un ampli/ampli-tuner audio-vidéo de la même manière qu’une enceinte conventionnelle. (le + sur le + et le - sur le -).ENTRETIEN DE VOS ENCEINTESL'ébenisterie de vos enceintes Infinity est recouvert d'un placage vinyl de haute qualité nécessitant peu d'entretien.Dépoussiérez l’ébénisterie avec un chiffon humide ou un produit de nettoyage pour meubles. Les grilles peuvent être passées àl’aspirateur, réglé sur la puissance minimale.EN CAS DE PROBLEMES DANS VOTRE SYSTEME STÉRÉOAvant d’appeller votre revendeur, le service consommateurs d’Infinity ou le distributeur Infinity de votre pays, vous pouvez réaliser quelques tests afin de localiser et résoudre certains problèmes concernant vos enceintes. Vous pouvez utiliser simplement les deux canaux stéréo de votre ampli pour découvrir l’origine de la panne : en cas de son distordu, l’écoute séparée de chaque enceinte permet de savoir si le problème est présent des deux côtés ou d’un seul. Dans le premier cas, le problème provient sans doute d’un autre élément de votre chaîne. S’il ne concerne qu’une voie, essayez d’inverser les sorties de l’ampli. Si la distorsion passe sur l’autre enceinte, làencore, le problème ne vient pas des écoutes mais réside plus en amont dans la chaîne.PROBLEMES CONCERNANT LES ENCEINTESSi une voie (tweeter, médium, boomer) de votre enceinte ne fonctionne pas, retirez le haut parleur correspondant de son logement et vérifiez que les fils sont bien solidaires des cosses du HP.Si ce n’est pas le cas, rebranchez-les et soudez-les correctement. Si les branchements sont corrects mais que le haut parleur ne fonctionne quand même pas, débranchez-le, retirez-le et remplacez-le par son homologue de l’autre enceinte. Si cela résout le problème, installez le haut-parleur suspect dans l’enceinte dont vous avez extrait ce HP de remplacement. S'il ne fonctionne pas mieux, vous pouvez être certain que c’est bien lui qui est défectueux et qu’il faut le remplacer.RÉPARATIONSPour tous problèmes de réparations, rapportez vos enceintes au revendeur chez qui vous avez effectué l’achat. Si, pour une raison ou une autre, cela n’était pas possible, contactez votre distributeur Infinity local.Harman France - Z.A du Parc Terminal - 9 rue St Just -93135 NOISY LE SEC Cedex9。
宝丽亚说明书
【商品名称】宝丽亚吸入用丙酸倍氯米松混悬液【通用名】吸入用丙酸倍氯米松混悬液【生产厂家】意大利凯西制药Chiesi Farmaceutici S.p.A.【产品类型】新药特药【成份】吸入用丙酸倍氯米松混悬液主要成分为丙酸倍氯米松。
【药品性状】吸入用丙酸倍氯米松混悬液为白色或类白色混悬液。
【适应症】吸入用丙酸倍氯米松混悬液为人工合成的强效肾上腺皮质激素类药物，是倍氯米松的二丙酸酯，具有抗炎、抗过敏、止痒等作用，能抑制支气管渗出物，消除支气管粘膜肿胀，解除支气管痉挛。
【药理毒理】生殖毒性：大鼠中口服16 mg/kg/day（以体表面积mg/m2计算，接近200倍最大成人推荐剂量）丙酸倍氯米松可引起受孕降低。
给予0.5 mg/kg/day的口服剂量（以体表面积mg/m2计算，接近20倍最大成人推荐剂量），通过抑制其性周期而损害其生殖力。
以0.33 mg/kg/day（以体表面积mg/m2计算，接近15倍最大成人推荐剂量）的剂量以吸入方式给予丙酸倍氯米松，在狗吸入使用12个月后没有抑制其性周期。
正如其他皮质类固醇，小鼠皮下给予0.1 mg/kg/day，家兔0.1 mg/kg/day及0.025 mg/kg/day，会出现致畸现象及胚胎毒性。
以体表面积mg/m2计算，小鼠和家兔的剂量大约只有成年人每天最大推荐吸入剂量的一半。
大鼠吸入给予15 mg/kg/day的剂量（以mg/m2计算，大约是成人最大推荐剂量的190倍），大鼠没有出现致畸现象及胚胎毒性。
致畸性：丙酸倍氯米松气雾剂没有诱发细菌细胞或哺乳动物体外中国仓鼠卵巢（CHO）细胞的基因突变。
在CHO细胞试管内培养或在大鼠细胞核内的体内培养没有发现明显的致畸性。
致癌性：大鼠中进行为期95周的致癌性评价，13周吸入剂量为0.4 mg/kg/day的丙酸倍氯米松，余下的82周里进行口服及同时吸入2.4 mg/kg/day的丙酸倍氯米松，在该试验中没有出现致癌性。
Jevtana 和 Cabazitaxel 产品说明书
Cabazitaxel:Jevtana®; Cabazitaxel§(Intravenous)Document Number: IC‐0074 Last Review Date: 02/02/2023Date of Origin: 01/2012Dates Reviewed: 06/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014,09/2014, 12/2014, 03/2015, 05/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016, 02/2017,05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 04/2019, 04/2020, 04/2021, 04/2022, 02/2023I.Length of AuthorizationCoverage will be provided for 6 months and may be renewed.II.Dosing LimitsA.Quantity Limit (max daily dose) [NDC unit]:-Jevtana 60 mg solution for injection, single-dose vial: 1 vial per 21 day supply-Cabazitaxel 45 mg/4.5 mL solution for injection, multiple-dose vial: 1 vial per 21 day supply-Cabazitaxel 60 mg/6 mL solution for injection, multiple-dose vial: 1 vial per 21 day supplyB.Max Units (per dose and over time) [HCPCS Unit]:-Jevtana: 60 billable units per 21 days-Cabazitaxel: 50 mg per 21 daysIII.Initial Approval Criteria 1,2Coverage is provided in the following conditions:∙Patient is at least 18 years of age; ANDUniversal Criteria 1-4∙Must be used in combination with a steroid (e.g. prednisone or dexamethasone); AND∙Patient does not have severe hepatic impairment (e.g., total bilirubin > 3 times the upper limit of normal); ANDProstate Cancer † 1-4∙Patient has castration-resistant metastatic adenocarcinoma; ANDo Used as a single agent †; AND▪Patient must have been previously treated with docetaxel unless not a candidate for or intolerant to docetaxel; ORo Used in combination with carboplatin ‡; AND▪Used for fit patients with aggressive variant disease (e.g., visceral metastases, low prostate-specific antigen and bulky disease, high LDH, high CEA, lytic bonemetastases, neuroendocrine prostate cancer histology) or unfavorable genomics(e.g., defects in at least two of the following: PTEN, TP53, and RB1); ANDPatient has received prior docetaxel and no prior novel hormone therapy(e.g., abiraterone, enzalutamide, darolutamide, apalutamide, etc.); ORPatient has received prior novel hormone therapy and no prior docetaxel; ORPatient has received prior docetaxel and prior novel hormone therapy; AND -Patient does not have visceral metastases; OR∙Patient has castration-resistant metastatic small cell/neuroendocrine prostate cancer;ANDo Used in combination with carboplatin; ANDo Used for fit patients with aggressive variant disease (e.g., visceral metastases, low prostate-specific antigen and bulky disease, high LDH, high CEA, lytic bonemetastases, neuroendocrine prostate cancer histology) or unfavorable genomics (e.g.,defects in at least two of the following: PTEN, TP53, and RB1)† FDA Approved Indication(s); ‡ Compendia recommended indication(s); Ф Orphan DrugIV.Renewal Criteria 1,2Coverage can be renewed based upon the following criteria:∙Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performancestatus, etc. identified in section III; AND∙Disease response with treatment as defined by lack of disease progression, improvement in tumor size and/or improvement in patient symptoms; AND∙Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: bone marrow suppression (neutropenia, anemia, thrombocytopenia, and/or pancytopenia), severe hypersensitivity reactions, gastrointestinal adverse reactions (severe diarrhea,nausea, vomiting), urinary disorders including severe hemorrhagic cystitis, renal failure,hepatic impairment, respiratory disorders (interstitial pneumonia/pneumonitis, interstitial lung disease, acute respiratory distress syndrome), etc.V.Dosage/Administration 1,2Prostate Cancer JevtanaAdminister 20-25 mg/m², intravenously, every 3 weeks in combination with an oral corticosteroidCabazitaxelAdminister 20 mg/m², intravenously, every 3 weeks in combination with an oral corticosteroidVI.Billing Code/Availability InformationHCPCS code:∙J9043 – Injection, cabazitaxel, 1 mg: 1 billable unit= 1 mg (Jevtana ONLY)∙J9999 – Not otherwise classified, antineoplastic drugs (Cabazitaxel ONLY)NDC:∙Jevtana 60 mg/1.5 mL solution for injection, single-dose vial: 00024-5824-xx∙Cabazitaxel 45 mg/4.5 mL solution for injection, multiple-dose vial: 00781-3186-xx §∙Cabazitaxel 60 mg/6 mL solution for injection, multiple-dose vial: 00781-3193-xx §§ Designated products approved by the FDA as a 505(b)(2) NDA of the innovator product. These products are not rated as therapeutically equivalent to their reference listed drug in the Food and Drug Administration’s (FDA) Orange Book and are therefore considered single source products based on the statutory definition of “single source drug” in section 1847A(c)(6) of the Act. For a complete list of all approved 505(b)(2) NDA products please reference the latest edition of the Orange Book:Approved Drug Products with Therapeutic Equivalence Evaluations | Orange Book | FDAVII.References1.Jevtana [package insert]. Bridgewater, NJ; Sanofi-Aventis U.S. LLC; February 2021.Accessed January 2023.2.Cabazitaxel [package insert]. Princeton, NJ; Sandoz Inc.; January 2023. Accessed January20233.Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCNCompendium®) for cabazitaxel. National Comprehensive Cancer Network, 2023. TheNCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONALCOMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® aretrademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to . Accessed January 2023.4.Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCNCompendium®) for Prostate Cancer 1.2023. National Comprehensive Cancer Network,2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®.NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCNGUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to. Accessed January 2023.5.Fahrenbruch R, Kintzel P, Bott AM, et al. Dose Rounding of Biologic and CytotoxicAnticancer Agents: A Position Statement of the Hematology/Oncology PharmacyAssociation. J Oncol Pract. 2018 Mar;14(3):e130-e136.6.de Bono JS, Oudard S, Ozguroglu M, et al; TROPIC Investigators. Prednisone pluscabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010. Oct2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.7.Sartor AO, Oudard S, Sengelov L, et al. Cabazitaxel vs docetaxel in chemotherapy-naive(CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA). Journal of Clinical Oncology34, no. 15_suppl(May 20,2016)5006-5006. DOI: 10.1200/JCO.2016.34.15_suppl.5006.8.Fizazi K, Kramer G, Eymard JC, et al. Quality of life in patients with metastatic prostatecancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of randomized multicentre, open-label, phase 4 study. Lancet Oncol. 2020Nov;21(11):1513-1525. doi: 10.1016/S1470-2045(20)30449-6.9.Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III Study Comparing a ReducedDose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) inPostdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol. 2017 Oct 1;35(28):3198-3206. doi: 10.1200/JCO.2016.72.1076. Appendix 1 – Covered Diagnosis Codes1010C61 Malignant neoplasm of prostateC7A.1 Malignant poorly differentiated neuroendocrine tumorsC7A.8 Other malignant neuroendocrine tumorsAppendix 2 – Centers for Medicare and Medicaid Services (CMS)Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs) and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: https:///medicare-coverage-database/search.aspx. Additional indications may be covered at the discretion of the health plan.Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/AJurisdiction Applicable State/US Territory ContractorE (1) CA, HI, NV, AS, GU, CNMI Noridian Healthcare Solutions, LLCF (2 & 3) AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ Noridian Healthcare Solutions, LLC5 KS, NE, IA, MO Wisconsin Physicians Service Insurance Corp (WPS)6 MN, WI, IL National Government Services, Inc. (NGS)H (4 & 7) LA, AR, MS, TX, OK, CO, NM Novitas Solutions, Inc.8 MI, IN Wisconsin Physicians Service Insurance Corp (WPS) N (9) FL, PR, VI First Coast Service Options, Inc.J (10) TN, GA, AL Palmetto GBA, LLCM (11) NC, SC, WV, VA (excluding below) Palmetto GBA, LLCNovitas Solutions, Inc.L (12) DE, MD, PA, NJ, DC (includes Arlington &Fairfax counties and the city of Alexandria in VA)K (13 & 14) NY, CT, MA, RI, VT, ME, NH National Government Services, Inc. (NGS)15 KY, OH CGS Administrators, LLC。
吸入用丙酸倍氯米松混悬液-宝丽亚说明书
性皮质激素，如有感染时，给予足量的抗生素以及B-受体激动剂治疗。
不得突然停用吸入用丙酸倍氯米松混悬液的治疗。
建议接受吸入性皮质激素长期治疗的儿童，应定期对身高进行监测。如果生长迟缓，应当审 核治疗，从而将吸入性皮质激素的剂量降低至能够维持哮喘有效控制的最低剂量。此外，应 考虑将患者转诊给儿科呼吸专家进行检查。
宝丽亚吸入用丙酸倍氯米松混悬液
【通用 吸入用丙酸倍氯米松混悬液
名】
【生产
意大利凯西制药Chiesi Farmaceutici
厂家】
【产品
新药特药
类型】
【成
吸入用丙酸倍氯米松混悬液主要成分为丙酸倍氯米松
份】
【药品
吸入用丙酸倍氯米松混悬液为白色或类白色混悬液 性状】
吸入用丙酸倍氯米松混悬液为人工合成的强效肾上腺皮质激素类药物，是倍氯米松的二丙酸
大推荐剂量的190氯米松气雾剂没有诱发细菌细胞或哺乳动物体外中国仓鼠卵巢（CHO细胞
的基因突变。在CHOS胞试管内培养或在大鼠细胞核内的体内培养没有发现明显的致畸性。
致癌性：大鼠中进行为期95周的致癌性评价，13周吸入剂量为mg/kg/day的丙酸倍氯米松， 余下的82周里进行口服及同时吸入mg/kg/day的丙酸倍氯米松，在该试验中没有出现致癌
感染和传染性疾病：很常见：口腔和咽喉部位的念珠菌病。
免疫系统病症：过敏反应，具有下述表现：不常见：皮疹、荨麻疹、瘙痒、红斑；非常罕见：
眼睛、面部、唇部和咽喉水肿，呼吸系统症状（呼吸困难和/或支气管痉挛），类过敏反应/
过敏反应。
内分泌病症：非常罕见：库欣综合征、类库欣综合征、肾上腺功能抑制、儿童和青少年生长
ASSA ABLOY 安全门系统产品说明书
HIGH SAFETYSafety contact edge or touchless safety edge. Safety limit switches according to PLe and SIL3.HIGH RELIABILITYHigh reliability and low service even after years of high numbers of cycles.HIGH SPEEDRapid opening and closing ensuresshort cycle time.ASSA ABLOY, Besam, Crawford, Albany and Megadoor, as words and logos, are examples of trademarks owned by ASSA ABLOY Entrance Systems or companies within the ASSA ABLOY Group.Machine Protection Door Albany RP300 / RP300 Wide / RP300 USD■R apid opening and closing ensures short cycle times up to 5 cycles per minute■H igh reliability even after years of high numbers of cycles■S afety limit switches according to EN ISO 13849-1 and EN 62061■D oors conform to EN ISO 12100 and EN ISO 14119■V ersions conforming to various factory standards are possible■T ype tested machine protection door with fabric door bladeAdvantages of the doorDesign SIDE FRAMESThe side frames are made of aluminum profiles.The front cover side frame can easily be removedand allows easy access for inspection and mainte-nance.DOOR CURTAINDepending on the application, various doorcurtains and colors are available (see details in thetable). From partially transparent PVC curtains withcolored reinforcement stripes with a high degreeof transparency to highly rigid RollTex® and No-maTex®. All door curtains are silicon-free.Side-mounted wind tabs reduce inward bending ofthe door blade. RollTex® according to TRAV (techni-cal rules for use of anti-fall guard vitrification).WINDOWSFor process monitoring when the door is closed,various window variants are available. On PVCcurtains with colored reinforcement strips, thereare large viewing areas. For all other variants ofcurtains, optional horizontal or vertical windowsare integrated in the door curtain. Also anti-UVwindows conform to EN 1598.DRIVE UNITGear motor with safety gear box including catchingdevice, mounted on the right or left side.CONTROL SYSTEMDepending on the application there are 2 controlsystems which offer a broad spectrum of speeds,power supplies and options for connecting controland safety devices.Standard: ACS 50Option: frequency converter control MCCUpon request the door can also be deliveredwithout a control system (not Upside Down).Extension box: Space saving extension box forMCC allows mounting of interface card or safetymonitoring module for safety limit switches.SAFTEY LIMIT SWITCH INTEGRATEDIN SIDE FRAMEFor the indication “door safely closed”, safety limit switches are integrated in the side frame. Optional evaluation by safety systems of the machi-ne (version without safety monitoring module). Due to the use of safety limit switches, m achine protection doors cannot be e quipped with a knock-out mechanism.MOTOR COVER AND TOP ROLL COVERMotor cover is made of powder coated steel plate (RAL 9006). Top roll cover is made of aluminium.MODEL ALBANY RP300 USDThe new Albany RP300 USD (Upside Down) ma-chine protection door is designed so that you can integrate it into your production area where bigger components and machinery must be arranged vertically.INTEGRATED CABLE CHAINIntegrated cable chain guides cables for pre-running photocell or electrical safety contact edge inside the side frame.MANUAL ACTIVATIONDuring a power failure the door can be opened manually using a hand crank.SAFETY FEATURESThe bottom profile is monitored by an electrical safety contact edge. As an option, the door can be equipped with a pre-running photocell in combi-nation with the control system MCC (Standard on Upside Down). A door line photocell also prevents the door from closing when objects are interfering. CE GUIDELINESThis door is designed according to the regulations of the Workplace Directive of the UVV as well as the harmonized CE Guidelines including the EN 13241-1 and 2006/42/EG.INDICATION OF RISKThe security of the door is designed for normal use for vehicles in industrial environments correspon-ding to the harmonized CE-Guidelines. In addition, special environmental conditions may impact the type of door necessary. For clarification and details, please contact your local sales engineer.Floor mounting brackets The door can be mounted free-standing on floor with optional mounting brackets. Levelling screws allow adjustment byuneven floor.Motor position Motor can be mounted right- or lefthand side. Motor position can be chosen in step of 45°. A chain drive is available as option in case of space limitations.Saftey limit switch Optional: For the indication “door safely closed”, safety limit switches are integrated in the side frame. Technical Data Albany RP300 / RP300 Wide / RP300 USD• Option ✓ Standard *) Specific number of cycles on request1) F or doors of height < 2300 mm the use of top roll cover is required according to standard EN 13241-1.2) Deviations possible depending on other properties3) Depending on cycles/minute, door size and installation locationThe Albany RP300 USD closes from bottom to topThe demands in automated manufacturing processes are high and the smallest interruption or delay can break down the flow of production or endanger employees. Machine protection doors help manufacturers avoid both scenarios. The doors are integrated into the processes and open and close according the production run. They enable the rapid change from complete isolation of the production step to free access to work piece and machine within seconds. It allows short cycle times and can be installed in machines, on production lines and railing systems wi-thin close proximity to the machine. Plus, they protect people in highly automated areas, making processes much safer.Advantages of the Albany RP300/RP300 Wide/RP300 USD■ S ervice friendly: Two-pieced aluminum side frames offer easy accessfor inspection and maintenance■ P re-running photocell: in combination with control system AlbanyMCC a pre-running photocell is available as option. It provides more comfort and higher closing speed■I ntegrated cable chain: The cables of the electrical safety contact edge and pre-running photocell are guided in cable chains inside the side frame■P luggable cables in the cable chain ■D rive unit: A chain drive is available as option in case of space limita-tionsConnection with the machine The in- and outputs of the door control unit MCC (potential 24 V DC) can be connected directly, to the machine. The in- and outputs of the door control unit MCC and ACS 50 can be connected potentialfree with the machine. As standard the following signals are available:■2 potential-free safety contacts, when the door is closed (safety limit switch)■ 1 output or potential-free signal, when the door is open■ 1 output or potential-free signal when the door is closed■ 1 output or potential-free signal for faults Example of use: door in assembly lineExample of use: place a workpiece into the processGeneral drawing Albany RP300[ ] = S pace needed for installationwithout coverwith MCC / side frame with window9300R0009/a9300R0022/0[ ] = S pace needed for installationFollow us:Please enter ASSA ABLOY Entrance in the channel’s search field.For subsidiary or representatives in your region visit:AAES productionAAES Reseller© A S S A A B L O Y E n t r a n c e S y s t e m s A B B R .M A N /A l b a n y R P 300 W i d e / D E U .E N -1.1/1608 / 64 100 728 T e c h n i c a l d a t a s u b j e c t t o c h a n g e w i t h o u t n o t i c e ASSA ABLOY Entrance Systems ***********************。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
【商品名称】宝丽亚吸入用丙酸倍氯米松混悬液
【通用名】吸入用丙酸倍氯米松混悬液
【生产厂家】意大利凯西制药Chiesi Farmaceutici S.p.A.
【产品类型】新药特药
【成份】吸入用丙酸倍氯米松混悬液主要成分为丙酸倍氯米松
【药品性状】吸入用丙酸倍氯米松混悬液为白色或类白色混悬液。
【药理毒理】吸入用丙酸倍氯米松混悬液为人工合成的强效肾上腺皮质激素类药物，是倍氯米松的二丙酸酯，具有抗炎、抗过敏、止痒等作用，能抑制支气管渗出物，消除支气
管粘膜肿胀，解除支气管痉挛。
【毒理研究】：
生殖毒性：大鼠中口服16 mg/kg/day（以体表面积mg/m2计算，接近200倍最大成人推荐剂量）丙酸倍氯米松可引起受孕降低。
给予0.5 mg/kg/day的口服剂量（以体表面积mg/m2 计算，接近20倍最大成人推荐剂量），通过抑制其性周期而损害其生殖力。
以0.33 mg/kg/day （以体表面积mg/m2计算，接近15倍最大成人推荐剂量）的剂量以吸入方式给予丙酸倍氯米松，在狗吸入使用12个月后没有抑制其性周期。
正如其他皮质类固醇，小鼠皮下给予0.1 mg/kg/day，家兔0.1 mg/kg/day及0.025 mg/kg/day，会出现致畸现象及胚胎毒性。
以体表面积mg/m2计算，小鼠和家兔的剂量大约只有成年人每天最大推荐吸入剂量的一半。
大鼠吸入给予15 mg/kg/day的剂量（以mg/m2计算，大约是成人最大推荐剂量的190倍），大鼠没有出现致畸现象及胚胎毒性。
致畸性：丙酸倍氯米松气雾剂没有诱发细菌细胞或哺乳动物体外中国仓鼠卵巢（CHO）细胞的基因突变。
在CHO细胞试管内培养或在大鼠细胞核内的体内培养没有发现明显的致畸性。
致癌性：大鼠中进行为期95周的致癌性评价，13周吸入剂量为0.4 mg/kg/day的丙酸倍氯米松，余下的82周里进行口服及同时吸入2.4 mg/kg/day的丙酸倍氯米松，在该试验中没有出现致癌性。
【药代动力学】药代动力学研究显示：吸入高剂量丙酸倍氯米松后仅20 - 25%的药物被吸收。
部分剂量被吞咽并经粪便排泄。
吸收进入循环中的部分药物经肝脏途径代谢为单丙酸盐和乙醇倍氯米松，然后以非活性代谢产物的形式经胆汁和尿液排泄。
【适应症】
吸入用丙酸倍氯米松混悬液适用于治疗哮喘及改善支气管阻塞症状。
【用法用量】
成人：单剂量药瓶经雾化器给药，每次1支，每天1 - 2次。
儿童：单剂量药瓶的一半剂量经雾化器给药，每次0.5支，每天1 - 2次。
单剂量药瓶上用刻度标记出一半剂量。
使用前请充分摇匀。
【不良反应】
下面按系统器官分类和频率列出不良事件。
频率定义为：很常见（1/10）；常见（1/100和<1/10）；不常见（1/1000和<1/100）；罕见（1/10000和<1/1000）；非常罕见（<1/10000），包括孤立报告和未知（从现有数据无法估计）。
非常常见、常见和不常见的不良事件一般是
从临床试验数据计算的。
在估计这些频率时，没有考虑在安慰剂组和对照组中的发生率。
罕见和非常罕见的不良事件一般是从自发报告数据计算的。
感染和传染性疾病：很常见：口腔和咽喉部位的念珠菌病。
免疫系统病症：过敏反应，具有下述表现：不常见：皮疹、荨麻疹、瘙痒、红斑；非常罕见：眼睛、面部、唇部和咽喉水肿，呼吸系统症状（呼吸困难或支气管痉挛），类过敏反应/ 过敏反应。
内分泌病症：非常罕见：库欣综合征、类库欣综合征、肾上腺功能抑制、儿童和青少年生长迟缓、骨密度降低、白内障、青光眼。
精神病症：主要是儿童。
非常罕见：焦虑、睡眠障碍、行为改变，包括活动亢进和易激惹；未知：抑郁、激越。
呼吸系统、胸部和纵隔病症：常见：声音嘶哑/咽喉刺激；非常罕见：反常性支气管痉挛。
吸入用丙酸倍氯米松混悬液经雾化吸入给药后，一些患者可能会发生口腔或咽喉部位的念珠菌病（鹅口疮），在丙酸倍氯米松剂量超过400 ug/天时，此并发症的发生率增加。
念珠菌沉淀素血液水平在病史或实验室检查数据中较高的患者，表明曾感染过念珠菌，更容易发生此并发症。
念珠菌病的发生率似乎与给药剂量有关。
患者可能会发现在使用吸入用丙酸倍氯米松混悬液后用水清洗口腔能明显降低上述真菌感染的发生。
有症状的念珠菌病可以采用局部抗真菌治疗，同时继续使用吸入用丙酸倍氯米松混悬液治疗。
吸入性皮质激素可能会发生全身性效应，特别是以高处方剂量长期用药时。
可能的全身性效应包括库欣综合征、类库欣综合征、肾上腺功能抑制、儿童和青少年生
长迟缓、骨密度降低、白内障和青光眼。
气道敏感性极高的患者，使用吸入用丙酸倍氯米松混悬液可能会引起咳嗽加剧和声音嘶哑或咽喉刺激，在吸入后立即用水清洗口腔可能是有益的。
如使用其他吸入治疗一样，在给药后可能会发生反常性支气管痉挛伴随喘鸣立即增多、气短以及给药后咳嗽。
这种情况应当立即用速效吸入性支气管扩张剂进行治
疗。
应立即停用吸入用丙酸倍氯米松混悬液，对患者进行评估，必要时开始使用替代治疗。
已有报道的过敏反应包括皮疹、荨麻疹、瘙痒、红斑，以及眼晴、面部、嘴唇和咽喉水肿。
可能发生的精神障碍包括精神亢奋、睡眠障碍、焦虑、抑郁、激越、行为改变（主要是儿童），发生率未知。
【禁忌症】
活动期或静止期局部病毒和结核感染的患者。
对本品中任何成份过敏的患者。
通常妊娠与哺乳期患者禁用。
【注意事项】
吸入性皮质激素可能会发生全身性效应，特别是以高处方剂量进行长期用药时。
但这些效应发生的可能性远远低于使用口服皮质激素时发生的可能性。
可能的全身效应包括库欣综合征、类库欣综合征、肾上腺功能抑制、儿童和青少年生长迟缓、骨密度降低、白内障、青光眼以及一些更罕见的心理或行为方面的作用，如精神亢奋、睡眠障碍、焦虑、抑郁或激越（特别是儿童）。
因此重要的是，吸入性皮质激素的剂量应调整至维持哮喘有效控制的最低剂量。
鼻腔或副鼻窦感染不是吸入用丙酸倍氯米松混悬液的禁忌症，但应采取适当的治疗。